Načítá se...
Navigating the Fas lane to improved cellular therapy for cancer
Genetically engineered T cells have shown promising activity in the treatment of cancer. However, these cells are also potentially susceptible to immune-suppressive pathways in the tumor microenvironment that may limit their efficacy. In this issue of the JCI, Yamamoto et al. describe a new cellular...
Uloženo v:
| Vydáno v: | J Clin Invest |
|---|---|
| Hlavní autor: | |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society for Clinical Investigation
2019
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6436865/ https://ncbi.nlm.nih.gov/pubmed/30830880 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1172/JCI127581 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|